Eqis Capital Management Inc. Grows Stake in Hologic, Inc. (NASDAQ:HOLX)

Eqis Capital Management Inc. increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 5.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,906 shares of the medical equipment provider’s stock after purchasing an additional 421 shares during the quarter. Eqis Capital Management Inc.’s holdings in Hologic were worth $526,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Nuveen Asset Management LLC grew its holdings in Hologic by 3.2% during the 2nd quarter. Nuveen Asset Management LLC now owns 3,660,892 shares of the medical equipment provider’s stock valued at $208,671,000 after buying an additional 112,055 shares in the last quarter. Marshall Wace North America L.P. grew its holdings in Hologic by 16.7% during the 2nd quarter. Marshall Wace North America L.P. now owns 2,642,914 shares of the medical equipment provider’s stock valued at $150,647,000 after buying an additional 378,729 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in Hologic by 57.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 1,567,138 shares of the medical equipment provider’s stock valued at $89,327,000 after buying an additional 573,858 shares in the last quarter. ArrowMark Colorado Holdings LLC purchased a new position in Hologic during the 2nd quarter valued at approximately $88,797,000. Finally, Deerfield Management Company L.P. Series C purchased a new position in Hologic during the 2nd quarter valued at approximately $78,101,000. Hedge funds and other institutional investors own 93.69% of the company’s stock.

HOLX has been the subject of several analyst reports. Wells Fargo & Company raised their price objective on Hologic from $80.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, November 5th. Smith Barney Citigroup raised their price objective on Hologic from $90.00 to $85.00 in a research note on Thursday, November 5th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research note on Monday, July 27th. Morgan Stanley raised their price objective on Hologic from $68.00 to $80.00 and gave the company an “equal weight” rating in a research note on Monday, November 9th. Finally, Jefferies Financial Group raised their price objective on Hologic from $80.00 to $98.00 in a research note on Thursday, November 5th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $77.56.

HOLX stock opened at $68.99 on Friday. The company has a current ratio of 1.47, a quick ratio of 1.17 and a debt-to-equity ratio of 1.22. Hologic, Inc. has a 12-month low of $26.49 and a 12-month high of $77.49. The company has a market cap of $17.73 billion, a price-to-earnings ratio of 16.43, a PEG ratio of 1.04 and a beta of 1.39. The firm has a 50 day moving average of $69.19 and a 200-day moving average of $61.58.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.85. Hologic had a return on equity of 47.83% and a net margin of 29.53%. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.11 billion. During the same period in the previous year, the firm posted $0.65 EPS. The company’s quarterly revenue was up 55.6% compared to the same quarter last year. Sell-side analysts forecast that Hologic, Inc. will post 4.33 earnings per share for the current fiscal year.

In related news, insider Benjamin Jordan Cohn sold 5,000 shares of Hologic stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $72.58, for a total transaction of $362,900.00. Following the completion of the transaction, the insider now directly owns 23,292 shares in the company, valued at approximately $1,690,533.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.00% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, surgical products, and light-based aesthetic and medical treatment systems for women in the United States and internationally. The company offers Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for acute respiratory ailments.

See Also: What is the CBOE Russell 2000® Volatility Index?

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.